巻号一覧
前身誌
60 巻, 8 号
選択された号の論文の8件中1～8を表示しています
- |<
- <
- 1
- >
- >|
-
松井 遵一郎1984 年 60 巻 8 号 p. 925-938
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーSuppressor T cell function induced by concanavalin A (con A) was evaluated in patients with Graves' disease and Hashimoto's thyroiditis. Patients with Graves' disease were divided into the following two groups : (1) untreated, and (2) euthyroid during anti-thyroid drug (methylmercaptoimidazole) therapy. T cells (2 × 105), activated by con A for 48 hours, were added to preincubated responder cells (2 × 105) and re-incubated for 7 days in the presence of pokeweed mitogen (PWM). IgG produced in the culture medium was measured by radioimmunoassay and then % suppressions (IgG) were calculated. Thyroid stimulating activity (TSA) in serum was measured by McKenzie's method by means of normal human thyroid slices, and % suppressions (c-AMP) were calculated.
IgG produced in lymphocyte culture medium was suppressed by added con A activated cells in untreated and euthyroid groups of Graves' disease, Hashimoto's thyroiditis and normal controls.
The value of % suppression (IgG) was reduced in each group of Graves' disease compared to normal controls. No significant relation was observed between TSA in serum and % suppression (IgG), but three cases with high serum TSA showd low % suppressions (IgG). In 12 cases of Graves' disease, % suppression (IgG) had a positive relation with % suppression (c-AMP) in same medium. The amount of c-AMP produced in thyroid slices incubated in medium, in which responder cells (8 × 105), was elevated in all 7 untreated cases of Graves' disease, while not elevated in 7 euthyroid cases. The value of % suppression (c-AMP) in euthyroid cases with Graves' disease was significantly higher than that in untreated cases.
The value of % suppression (IgG) was reduced and had a significant negative relation with logarithm of serum antimicrosomal antibody titer in patients with Hashimoto's thyroiditis.
These results indicate that low activity of suppressor T cell had a role on antibody production, including thyroid stimulating antibody, and pathgenesis of autoimmune thyroid diseases.抄録全体を表示PDF形式でダウンロード (1278K) -
山本 蒔子, 斉藤 慎太郎, 桜田 俊郎, 海瀬 和郎, 海瀬 信子, 吉田 克己, 深澤 洋, 鈴木 道子, 野村 隆, 板垣 洋一, 吉 ...1984 年 60 巻 8 号 p. 939-949
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーSerial changes of thyroid hormones, TSH, antithyroidal antibodies, serum Tg and TBII were studied in a patient with silent thyroiditis who experienced four episodes of transient thyrotoxicosis in a follow-up period of five years.
1) The titers of MCHA were high in the thyrotoxic episodes and further increased in the following hypothyroid phases. In the euthyroid phase it became lower.
2) The serum level of Tg was normal or moderately elevated in the thyrotoxic episodes, and it further elevated in the hypothyroid phase.
3) Surgical biopsy, performed in the euthyroid phase about one year after the forth thyrotoxic episode, revealed the findings of Hashimoto's disease.
4) Two different types of transient thyrotoxic episode, one with positive TBII and high uptake and the other with negative TBII and low uptake, were observed in the same patient with silent thyroiditis.
5) In the beginning of the clinical course, the patient showed positive 131I, high uptake (77%) in the second episode of thyrotoxicosis, no response of TSH to TRH administration and absence of T3-suppressibility.
6) The value of 131I gradually became normal and was negative at the forth episode of thyrotoxicosis when 131I-uptake was low (1.3%). After this last episode, TSH response to TRH administration was normal in euthyroid phase and augmented in hypothyroid phase.
7) The presence of transient positive TBII and of histological changes of Hashimoto's disease was suggestive of the close relationship between Graves' and Hashimoto's diseases.抄録全体を表示PDF形式でダウンロード (1369K) -
第I報基本的測定条件の検討今井 強一, 清水 嘉門, 山中 英寿1984 年 60 巻 8 号 p. 950-963
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーSpecific binding of the synthetic progestin 17α-methyl- [3H] -promegestone (R5020) in the cytosol of human benign prostatic hypertrophy was studied to determine the accurate quantitative assay method.
No significant effect was observed between Tris and Phosphate buffer during a buffer composition investigation. The addition of either glycerol or mercaptoethanol was effective in the enhancement of R5020 specific binding. When sodium molibdate was added into the incubation buffer, the obvious increase of 7-8S components in the SDG analysis was observed. R5020 specific binding was suppressed by the addition of CaCl2. No enhancement effect was observed by the addition of EDTA (0.1-6mM). Under the high concentration of EDTA (10-50mM), it was suppressed.
SDG assay by the vertical rotor was superior to that by the swing rotor. It seemed that the long incubation time was an important factor to obtain 7-8S, which was sufficiently bounded. This estimation, however, is not assertive. Further information on the incubation time frame will be presented in the next report.
It was evident that the 7-8S saturable peak alone was less than the value calculated by the charcoal assay. It was concluded that not only 7-8S but also 4S binding was included in N value by the charcoal assay. The SDG assay is recommended for the clinical receptor study, since there is not enough information concerning the charactor of 4S and 7-8S saturable binding in the human prostate.抄録全体を表示PDF形式でダウンロード (1225K) -
横江 敏雄, 桑山 明夫, 市原 薫, 山本 直人, 景山 直樹1984 年 60 巻 8 号 p. 964-970
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーSince Vale et al isolated and sequenced a 41 amino acid peptide with corticotropin-releasing factor (CRF) activity from ovine hypothalami, intensive works have been done about its physiological activity and intracerebral distribution.
However, little has been done yet about C ' F metabolism in human cerebrospinal fluid (CSF).
Using a specific ovine CRF radioimmunoassay (RIA), we measured the levels of CRF in CSF from 16 patients with Cushing's disease (group I), 8 patients with Acromegaly (group II), 5 patients with Prolactinoma (group III) and 10 patients without endocrine abnormalities (group IV). Moreover diurnal changes of CRF in CSF from 2 patients with Acromegaly and 2 patients with Cushing's disease were examined.
Dilution curves of CRF in CSF were parallel to that of synthetic ovine CRF standard. The intraassay coefficient of variation was 9.2% and the interassay coefficient of variation 12.6%.
The concentrations of CRF in CSF of groups I, II, III and IV were 38.83 ± 9.02 pg/ml (mean ± SD), 44.24 ± 4.71, 47.62 ± 8.05 and 49.45 ± 12.86, respectively.
Group I was significantly lower than group IV (p<0.05). On the other hand, group II or III was not significantly different from group IV. A diurnal rhythm of CRF in CSF was observed in 2 patients with Acromegaly.
However, there was almost no change in the 2 patients with Cushing's disease.
In considering rich amount of CRF in hypothalamus and CRF-positive fibers surrounding the third ventricle, CRF content in CSF seems to reflect mainly its metabolic activity in hypothalamus. Therefore, our results suggest that hypothalamic CRF metabolism in Cushing's disease is suppressed with the elimination of its diurnal activity by secondary hypercortisolism due to autonomic ACTH-hypersecretion from pituitary adenoma.抄録全体を表示PDF形式でダウンロード (552K) -
副甲状腺機能低下症患者における検討尾形 悦郎, 山本 通子, 松本 俊夫, 藤田 拓男, 深瀬 正晃, 木下 芳一, 古川 洋太郎, 孫 孝義, 中島 博徳, 安田 敏行1984 年 60 巻 8 号 p. 971-984
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーThe present study was undertaken to establish a standard method to perform the Ellsworth-Howard test using human PTH- (1-34). For this purpose we made a survey of literature concerning the Ellsworth-Howard test and then examined the data of the Ellsworth-Howard tests performed on 178 hypoparathyroid patients using human PTH- (1-34). The main items of investigation were : (i) to determine the appropriate dose of PTH for administration to adults and children; and (ii) to define the criteria of practical usefulness for the differential diagnosis of the types of hypoparathyroidism.
From the analysis of the data, the following findings and conclusions were obtained.
I) The dose of human PTH- (1-34) appropriate for diagnostic use is 100U per person for adults and 100U per body surface area of one square meter (100 U/m2) for children.
II) The criteria of positive response in the Ellsworth-Howard test are defined as follows.
a) phosphaturic response : (U4 + U5) - (U2 + U3) = more than 35 mg/2h b) cyclic AMP response : U4 -U3 = more than 1μmol/h, and
U4/U3 = more than 10 times
In the above formula, U2 -U5 represent the urine samples collected hourly in order. PTH is injected at the time between U3 and U4. For the application of the criteria in children, one should use the values corrected for body surface area of one square meter.
III) It is necessary to confirm the following conditions before the application of the criteria : (1) the presence of hypocalcemia and hyperphosphatemia; (2) the lack of phosphate deficiency (basal urinary phosphate excretion more than 10 mg/ 2 h); (3) the accuracy of timed urine collections (ratio of creatinine excretion during 2 hours before PTH to that after PTH administration in the range from 0.8 to 1.2); and (4) the absence of marked diurnal variation in phosphate excretion (difference in phosphate excretion between the two basal hourly urine less than 17.5 mg/h).
IV) To ensure the above conditions, medications such as phosphate-binding antacids should be withheld for at least 1 week before the test, and the test should be performed according to the standard procedure described in this paper.
V) The diagnosis of pseudohypoparathyroidism Type II should be done cautiously. It is necessary to take account of the high basal urinary cyclic AMP excretion and the elevated serum PTH level along with the results of the Ellsworth-Howard test (positive cyclic AMP response and negative phosphaturic response) for a definite diagnosis of this entity.抄録全体を表示PDF形式でダウンロード (1376K) -
奥野 晃正, 矢野 公一, 印鑰 史衛, 鈴木 豊, 田口 哲夫, 村田 光範, 百渓 尚子1984 年 60 巻 8 号 p. 985-994
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーAn improved method for plasma methimazole assay using high performance liquid chromatography is described. The plasma samples were treated with sodium bisulfite and ammonium sulfate prior to extraction with chloroform. This pretreatment of the samples raised the extraction coefficient to 90%, while simple extraction yielded only 55%. The minimal detection limit was 0.02 μg/ml, and the coefficient of variation at the level of 0.2 and 1.0 μg/ml was less than 5%.
Pharmacokinetics of methimazole was studied after a single oral dose (20 mg/m2) in six subjects including two healthy adults and four thyrotoxic children. Plasma levels of methimazole showed a peak concentration of 1.03 ± 0.25 μg/ml approximately one hour after the drug administration. Plasma half-life, area under the curve and distribution volume were 4.56 ± 0.71 hr, 7.05 ± 0.95 μg/ml × hr, and 630 ± 110 ml/kg respectively.抄録全体を表示PDF形式でダウンロード (873K) -
下垂体中葉遊離細胞における検討古木 義弘, 迫田 芳生, 畑田 泰行, 宗村 正英, 前山 昌男, 松村 光博1984 年 60 巻 8 号 p. 995-1004
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリーThe intermediate lobe cells of pituitary gland synthesize and secrete bioactive peptides derived from proopiomelanocortin. In the present study, we investigated the effects of cholera toxin on the release of β-endorphin (β-Ep) from dispersed-intermediate lobe cells of rats. Cholera toxin added into culture medium, enhanced the intracellular accumulation of adenosine 3', 5'-monophosphate (cAMP) and the release of β-endorphin like immunoreactive substance (β-END-LIS). A positive dose-response relationship existed between the concentration of cholera toxin and the release of j3-END-LIS or the accumulation of cAMP. Maximal response was obtained with approximately 3 × 10-10M (in β-END-LIS release) and 1 × 10-9M (in cAMP accumulation) concentration of cholera toxin. Incubation with cholera toxin (3 × 10-8M) resulted in a significant rise of cAMP accumulation after 20-30 min, and a 2-2.5 fold increase of β-END-LIS release occurred after 60 min in comparison with nontreated cells. cAMP analog and phosphodiesterase inhibitor also increased the β-END-LIS release10). These results suggested the close relationship between cAMP accumulation and its biological effect (i.e. β-END-LIS release).抄録全体を表示PDF形式でダウンロード (790K) -
大熊 新一1984 年 60 巻 8 号 p. 1005-1014
発行日: 1984/08/20
公開日: 2012/09/24
ジャーナル フリー1977年に当研究所で発見し, 維持を行っている自然発症矮小ラット (Spontaneous Dwarf Rat;以下矮小ラット) の特徴は1) 成熟時体重は同腹正常ラットの1/3～1/4である。2) 常染色体性劣性遺伝子により支配されている。3) 光顕レベルでの下垂体検査およびtibiatestなどにより, その原因は下垂体前葉のGH分泌細胞の欠損であると推察された。そこで, このことを確認するために以下の実験を行った。
1) porcine ACTH, ratPRL, ovineGH抗血清を用いた酵素抗体法により, 下垂体前葉中のACTH, PRLGH分泌細胞を免疫学的に同定した。2) 免疫組織化学法の1つである隣接切片対位法により, 下垂体前葉のGH, GTHおよびTsH分泌細胞を形態的に検索した。3) Disc電気泳動法により, 下垂体前葉中のGHとPRLを生化学的に同定した。
その結果, 矮小ラットにおいては1) ovineGH抗血清に反応する細胞は認められなかった。
2) 形態的にもGH分泌細胞は見られなかった。
3) 生化学的にもGHは認められなかった。
以上のことから, この矮小ラットでの成長不全の原因は免疫学的, 形態学的および生化学的にみて, 下垂体前葉中のGH分泌細胞の欠如に基づくGH単独欠損症であり, ヒトにおけるGH単独欠損症の好的な疾患モデル動物になりうると考えられる。
本実験を御指導していただいた東京慈恵会医科大学の石川博助教授並びに第二解剖学教室の方々に深謝いたします。抄録全体を表示PDF形式でダウンロード (4216K)
- |<
- <
- 1
- >
- >|